| Income Statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Research and development | 9,714 | 9,373 | 23,239* | 9,073 |
| Acquired in-process research and development, related party | - | - | 0* | 0 |
| General and administrative | 5,645 | 5,838 | 6,289* | 5,819 |
| Total operating expenses | 15,359 | 15,211 | 29,527 | 14,892 |
| Loss from operations | -15,359 | -15,211 | -29,527* | -14,892 |
| Interest income | 1,855 | 1,514 | 2,007* | 2,037 |
| Foreign currency loss (gain) | 6 | -25 | 2* | -33 |
| Total other income (expense) | - | - | 2,008* | - |
| Total other income, net | 1,861 | 1,489 | - | 2,004 |
| Net loss | -13,498 | -13,722 | -27,519* | -12,888 |
| Unrealized gain (loss) on marketable securities | -224 | -278 | 138* | 151 |
| Comprehensive loss | -13,722 | -14,000 | -27,382 | -12,737 |
| Basic EPS | -0.18 | -0.2 | -0.404 | -0.19 |
| Diluted EPS | -0.18 | -0.2 | -0.404 | -0.19 |
| Basic Average Shares | 76,154,071 | 68,207,313 | 67,848,066 | 68,003,248 |
| Diluted Average Shares | 76,154,071 | 68,207,313 | 67,848,066 | 68,003,248 |
Climb Bio, Inc. (CLYM)
Climb Bio, Inc. (CLYM)